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Background: There is little data on the survival of elderly patients with stage III non-small
cell lung cancer (NSCLC).
Methods: Patients with stage III NSCLC in the Netherlands Cancer Registry/Limburg from
January 1, 2002 to December 31, 2008 were included.
Findings: One thousand and two patients with stage III were diagnosed, of which 237 were
75 years or older. From 228 patients, co-morbidity scoreswere available. Only 33/237 patients
(14.5%) had no co-morbidities, 195 (85.5%) had one or more important co-morbidities, 60
(26.3%) two or more co-morbidities, 18 (7.9%) three or more co-morbidities and 2 patients
(0.9%) suffered from four co-morbidities. Forty-eight percent were treated with curative
intent. No significant difference in Charlson co-morbidity, age or gender was found between
patients receiving curative or palliative intent treatment. Treatmentwith curative intentwas
associatedwith increased overall survival (OS) compared to palliative treatment: median OS
14.2months (9.6–18.7) versus 5.2 months (4.3–6.0), 2-year OS 35.5% versus 12.1%, for curative
versus palliative treatment.
Findings: Patientswho received only radiotherapywith curative intent had amedian OS of
11.1 months (95% confidence interval [95% CI] 6.4–15.8) and a 5-year OS of 20.3%; for
sequential chemotherapy and radiotherapy, the median OS was 18.0 months (95% CI
12.2–23.7),witha5-yearOSof14.9%.Only fourpatients receivedconcurrent chemo-radiation.
Interpretation: In this prospective series treating elderly patients with stage III NSCLC with
curative intent was associated with significant 5-year survival rates.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.666; fax: +31 (0)88 44 55 667.
o.nl (D. De Ruysscher).
 the Elsevier OA license.
2692 E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 2 6 9 1 –2 6 9 71. Introduction Information on topography and morphology was codedNon-small cell lung cancer (NSCLC) remains one of the most
lethal and frequent cancers world-wide.1–3 The disease occurs
most frequently in the elderly population, with about 50% of
the patients being 70 years or older and approximately 25%
over the age of 74 years.1,2,4 With current demographic trends
both in Europe, the United States and in major Eastern coun-
tries, the absolute number and the proportion of elderly pa-
tients with lung cancer will further increase in the coming
decades.1,2 Because of the age distribution and the smoking
history of most lung cancer patients, the majority of them
present with major co-morbidities at the time of diagnosis,
which may render many patients not suitable for aggressive
treatments and which will lead to higher non-cancer related
deaths in this population.4,5
Although concurrent chemo-radiotherapy has become the
treatment with the best chance for long-term survival in pa-
tients with stage III NSCLC, there are scarce data on the out-
come of elderly patients treated with curative intent for stage
III NSCLC.6–13 Elderly patients entered in clinical trials consis-
tently showed more haematological toxicity than the younger
group, a finding which was also observed in advanced stage
elderly patients.8,9,12–15 Elderly patients also experienced
more non-haematological toxicity, although this varied be-
tween trials: In NCCTG 94-24-52, they had more pneumonitis,
more oesophagitis in RTOG 94-10, and more renal complica-
tions in CALGB 9130.8,9,13 Despite the increased level of toxic-
ity experienced by the elderly patients, their survival was
similar to that observed in younger individuals. The question
how to deal with the 75 years and older group with stage III
NSLC remains unanswered.16–19
In the present study, we investigated in a large prospective
population-based registry the outcome of patients treated
with curative or palliative intent.
2. Patients and methods
2.1. Netherlands Cancer Registry/ Limburg (NCR/L)
All patients with a pathological diagnosis of NSCLC20 in south
and middle Limburg and with stage III (UICC 6th Edition21)
from January 1, 2002 to December 31, 2008 were included.
Data were obtained from the population-based Netherlands
Cancer Registry (NCR) of the Comprehensive Cancer Centre
the Netherlands. The NCR/L is a population-based cancer reg-
istry, which was established in 1984 and is a department of
the Comprehensive Cancer Centre the Netherlands-Location
Maastricht. The NCR/L covers the region of mid and southern
Limburg, which is situated in the southeast of The Nether-
lands. On 1 January 2006, the region covered a total of
853,553 inhabitants. The main sources of information are re-
gional hospitals and pathology laboratories from which the
NCR/L receives reports on a weekly basis since 1986. After
receiving the notification reports, trained registration clerks
collect all relevant data of the patients and tumours from
the medical records.according to the International Classification of Diseases for
Oncology, 3rd Edition.21 Tumour stage was recorded in accor-
dance with the tumour–node–metastasis classification sys-
tem.21 Completeness of case ascertainment of the NCR/L is
very high; for lung cancer, this is estimated to be >95%.22
2.2. Co-morbidity
Co-morbidity of all lung cancer patients was scored using the
Charlson co-morbidity index (CCI).23 Co-morbidity was de-
fined as disease that was present at the time of diagnosis
and was prospectively retrieved from hospital records.
2.3. Staging and treatment
Only patients without a malignant pleural or cardiac effusion
were offered treatment with curative intent. Patients were
staged with a whole body 18F-deoxyglucose (FDG)-Positron
Emission Tomography (PET) scan and a CTor MRI of the brain
unless on a regular CT scan of the chest and the upper abdo-
men metastases were already visualised. Patients were trea-
ted according to standard regional protocols.
According to the regional guidelines, the treatment of
choice for patients with stage III (T4 and/or N2-3) NSCLC
was concurrent chemo-radiotherapy. Patients with T3N1M0
tumours were treated with a lobectomy and a lobe-specific
nodal dissection. Adjuvant chemotherapy was not applied
in the studied time period in elderly patients.
In practice, however, the multidisciplinary team, compris-
ing at least a pulmonologist specialised in lung cancer, a tho-
racic surgeon, a radiation oncologist, a radiologist, a nuclear
medicine specialist and a pathologist, was left free to choose
the most appropriate treatment for an individual patient.
Thus, elderly patients often received sequential chemother-
apy and radiotherapy, radiotherapy alone, chemotherapy
alone or best supportive care, which could include palliative
radiotherapy.
Sequential chemotherapy consisted of cisplatin
(75 mg/m2) or carboplatin (AUC 5) on day 1 and gemcitabine
1250 mg/m2 on day 1 and 8. Cycles were repeated every 21
days for a total of 3 cycles. The carboplatin dose in milligrams
was based on the target AUC (5) · (glomerular filtration
rate + 25), with the glomerular filtration rate calculated
according to the Cockroft–Gault formula. Standard dose-
reduction rules were applied if indicated. In non-progressive
patients (RECIST criteria), based on a CT scan of the chest,
the primary tumour and the involved lymph nodes were trea-
ted with radiotherapy.24 The dose was specified according to
ICRU 50 guidelines.25 From 2002 to 2005, radiotherapy con-
sisted of a dose of 60 Gy in 30 fractions in 6 weeks. From
2006, individualised accelerated radiotherapy to the primary
tumour and the pre-treatment involved lymph nodes on
FDG-PET-CT scan was given after induction chemotherapy.26
The mean radiation dose was 64.8 Gy given in 36 bi-daily frac-
tions of 1.8 Gy with at least 8 h of inter-fraction interval in an
overall treatment time of 3.6 weeks.27 This is a biological
Table 1 – TNM distribution.
T- and
N-distribution
n %
T0N3 3 1.3
T1N2 7 3.0
T1N3 5 2.1
T2N2 57 24.1
T2N3 24 10.1
T3N1 8 3.4
T3N2 21 8.9
T3N3 4 1.7
T4N0 36 15.2
T4N1 1 0.4
T4N2 54 22.8
T4N3 17 7.2
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8.2 weeks.
Also from 2006, concurrent chemo-radiation, after 2 cycles
or carboplatin-gemcitabine, concurrent cisplatin–vinorelbine
(cisplatin 50 mg/m2 day 2 and 9, vinorelbine 20 mg/m2 day 2
and 9, cisplatin 40 mg/m2 day 23, vinorelbine 15 mg/m2 day
23 and 30; day 1 is the first day of radiotherapy) and radiother-
apy to the primary tumour and the lymph nodes involved on
FDG-PET-CT was allowed for patients with a WHO perfor-
mance status 0–1 and without >10% weight loss over the last
6 months. Individualised accelerated radiotherapy with anal-
ogous normal tissue constraints as those for sequential che-
mo-radiotherapy was given.27 In the first three weeks, 30
twice-daily fractions of 1.5 Gy were given, followed by once-
daily fractions of 2 Gy until a mean lung dose of 19 Gy was
reached.28 A mean radiation dose to the tumour and the in-
volved lymph nodes of 65 Gy delivered in 5.5 weekswas given.
This corresponds to a biological equivalent of 74 Gy given in
36 daily fractions in 7.4 weeks.
For patients not treated with curative intent, the treatment
was left to the discretion of the treating physician. Both best
supportive care, which included palliative radiotherapy, and
chemotherapy, mainly consisting of carboplatin and gemcita-
bine were given. Targeted agents were not employed outside
of clinical trials in the time periods studied in the present
report.
2.4. Follow-up
Patients were seen by the pulmonologist or the radiation
oncologist the first weeks after the end of treatment until
the acute side-effects resolved to grade 1, and thereafter every
three months the first two years, every six months from year
3 to 5 and every year after 5 years. A CT scan or an X-ray of the
chest was done regularly or on indication.
2.5. Statistics
Survival was calculated from the date of diagnosis till death
using the Kaplan–Meier method with SPSS Statistics version
17.0. Median survival rates are expressed together with their
95% confidence intervals (CI). Other results are expressed as
mean ± standard deviation (SD) and their range. Differences
between proportions were calculated with Chi-square tests.
Differences with a p-value < 0.05 were considered significant.
The minimal follow-up of all patients is 2 years. Survival
was updated in January 2011.
3. Results
3.1. Patient characteristics
From January 1, 2002 to December 31, 2008, 1002 patients with
stage III NSCLC were diagnosed, of which 545 were less than
70 years old, 220 between 70 and 74 years and 237 75 years
or older.
The mean age of the elderly group, i.e. 75 years or older,
was 78.9 ± 3.5 years (range 75–90). One-hundred ninety-four
patients (81.9%) were male, and 43 (18.1%) female.
Seventy-four patients (31.2%) had stage IIIA NSCLC and 163(68.8%) stage IIIB. The detailed T- and N-stage is depicted in
Table 1.
NSCLC-not otherwise specified was the most frequent en-
tity with 108 patients (45.5%), followed by squamous cell can-
cer (87 patients; 36.7%), adenocarcinoma (40 patients; 16.8%)
and bronchiolo-alveolar carcinoma (2 patients; 0.8%).
Most tumours were located in the upper lobe (134 patients;
56.5%), 70 (29.5%) in the lower lobe, 17 (7.2%) in themain bron-
chus, 5 (2.1%) in the middle lobe, 4 (1.7%) growing directly
from one lobe in the adjacent lobe and from 7 patients
(3.0%), the exact location could not be retrieved. Hundred
thirty-four tumours (56.5%) were right-sided, 102 (43%) in
the left lung and in one patient unknown.
From 228 of the 237 (96.2%) elderly patients, co-morbidity
scores were available. Only 33 patients (14.5%) had no co-mor-
bidities, 195 (85.5%) had one or more important co-morbidi-
ties, 60 (26.3%) two or more co-morbidities, 18 (7.9%) three
or more co-morbidities and 2 patients (0.9%) suffered from
four co-morbidities. The most frequent co-morbidities were
chronic obstructive pulmonary disease (COPD) (73 patients;
32%); myocardial infarction (68 patients; 29.8%), another
malignancy in the medical history (62 patients; 27.2%), diabe-
tes mellitus (40 patients; 17.5%) and hypertension (48 pa-
tients; 21%). Co-morbidities are summarised in Table 2.
The co-morbidities in the 765 patients younger than
75 years with stage III NSCLC in our region were: No co-mor-
bidities: 242 patients (31.6%), one: 229 patients (29.9%), two:
150 patients (19.6%), three: 87 patients (11.4%), four: 13 pa-
tients (2.5%), five co-morbidities: 17 patients (2.2%), missing
co-morbidity score: 21 patients (2.7%). The elderly group
showed thus more co-morbidities, which were more often
multiple. The disease distribution in the co-morbidities was,
however, similar in the elderly than in the younger group, ex-
cept for malignancy in their medical history (data not shown).
3.2. Treatment
One hundred and thirteen patients (47.7%) were treated with
curative intent and 124 (52.3%) palliatively. Patients with stage
IIIA were more likely getting a treatment with curative intent
than individuals with stage IIIB: 46/75 (62.2%) versus 67/163
(41.1%), respectively; p < 0.001. From the 124 patients with a
T4 tumour, 50 were treated with curative intent (40.3%), in
Table 2 – Co-morbidities of all patients (n = 228).
Co-morbidity n %
None 33 14.5
COPD 73 32.0
Myocardial infarction 68 29.8
Other malignancy 62 27.2
65 yearsa 37 16.2
6–10 yearsa 11 4.8
>10 yearsa 14 6.1
Hypertension 48 21.0
Diabetes mellitus 40 17.5
Cardiac arrhythmia 34 14.9
Peripheral vascular disease 29 12.7
CVA 18 7.9
Cardiac failure 16 7.0
Cardiac valvular disease 15 6.6
Peptic ulcer 9 3.9
Thrombosis 7 3.1
Diverticulitis 3 1.3
Cardiomyopathy 3 1.3
Rheumatoid arthritis 2 0.9
Chronic inflammatory bowel disease 2 0.9
Dementia 2 0.9
Gastric resection 2 0.9
Psychiatric disorder 1 0.4
Tuberculosis 1 0.4
Parkinson’s’ disease 1 0.4
Glomerulonephritis 1 0.4
Haemodialysis 1 0.4
n = Number of patients.
COPD: Chronic Obstructive Pulmonary Disease.
CVA: Cerebral Vascular Accident.
a Years before current stage III NSCLC diagnosis.
Fig. 1 – Overall survival of patients 75 years or older with
stage III NSCLC treated with curative intent (n = 113, blue
line) or palliatively (n = 124, green line). (For interpretation of
the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 2 – Overall survival of patients 75 years or older with
stage III NSCLC according to different treatments. Blue: Best
supportive care (n = 85); Grey: Palliative chemotherapy
(n = 29); Green: Radiotherapy alone (n = 85); Red: Sequential
chemotherapy and radiotherapy (n = 51); Black: surgery
(n = 10). (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of
this article.)
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(53.2%) and in the N3 group 23 patients (43.4%). These differ-
ences are significantly different from each other (p < 0.001).
No significant difference in Charlson co-morbidity, age or
gender was observed between patients treated with curative
or palliative intent, with 50.3% of patients in the curative in-
tent group having two or more co-morbidities versus 59.7%
in the palliative group.
The median overall survival (OS) and the survival at
2 years were 14.2 months (95% CI 9.6–18.7) versus 5.2 months
(95% CI 4.3–6.0) and 35.5% versus 12.1%, for curative intent
versus palliative therapy, respectively (Fig. 1).
Patients who received only best supportive care (n = 85)
had a median OS of 3.6 months (95% CI 2.6–4.6), a 1-year
survival of 11.8%, a 2-year survival of 4.7% and no survivors
at 3 years. When palliative chemotherapy was given (n = 29),
the median OS was 7.7 months (95% CI 5.3–10.0), a 1-year
OS of 27.6%, a 2-year OS of 20.7% and 1 patient (8.3%) being
alive after 5 years. For 85 patients who received only
radiotherapy, the median OS reached 11.1 months (95% CI
6.4–15.8), with a 1-, 2-, and 5-year OS of 47.6%, 31.7% and
20.3%, respectively. Fifty-one patients received chemotherapy
and radiotherapy. As only four of them got concurrent che-
mo-radiation, these individuals were included in the same
group. Chemo-radiotherapy lead to a median OS of
18.0 months (95% CI 12.2–23.7), with a 1-year OS of 62.7%,
2-year OS of 39.2% and a 5-year OS of 14.9%.
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tumour and two with a T4N0 cancer because of multiple
nodes in the same lobe. The median OS in this group was
20.6 months (95% CI 0–43.4), with 1-, 2-, and 5-year survival
rates of 60%, 50% and 26.7%, respectively.3.3. Results are summarised in Fig. 2
Fourty-nine percent of patients younger than 75 years with
stage III NSCLC in the same region received treatment with
curative intent. This is thus the same as for the elderly. How-
ever, of the 765 younger patients, 84 (10.9%) were treated with
surgery only: 15 patients had a T4N0 cancer because of multi-
ple nodules in the same lobe and 64 had T3N1 disease. Thir-
teen patients received induction chemotherapy followed by
resection for the following stages: T1N2 (1 patient), T2N2 (7
patients), T4N2 (3 patients) and T2N3 (2 patients).
In the same younger age group in the same time period,
323 patients (42.2%) were treated with chemo-radiation, of
which 62 individuals with concurrent chemotherapy and
radiotherapy.
Best supportive care was given in 123 younger patients
(16.1%), chemotherapy alone in 174 patients (22.7% and radio-
therapy alone in 40 patients (5.2%).
The elderly thus received both less sequential and concur-
rent chemo-radiotherapy than the younger patients and were
more likely to be treated with high-dose radiotherapy alone.
4. Discussion
Lung cancer is increasingly a disease of the elderly. On a pop-
ulation basis, about 50% of the patients are over 70 years and
25% 75 years or older.1–4 In the present series, we investigated
the survival of 237 patients 75 years or older with stage III
NSCLC. As expected, only 14.5% of these patients did not have
co-morbidities. Forty-eight percent were treated with curative
intent. No significant difference in Charlson co-morbidity, age
or gender was found between patients receiving curative or
palliative intent treatment. The overall survival at 2-years
was 35.5% for patients treated with curative intent, compared
to 12.1% when treated palliatively. Interestingly, even in these
elderly stage III NSCLC patients, significant 5-year survival
rates could be achieved when treatment with curative intent
was given. When treated with radiotherapy only, 20.3% were
alive at 5 years, which was 14.9% with sequential chemother-
apy and radiotherapy.
Our results thus show that with proper patient selection,
reasonable long-term survival rates can be achieved when
treating elderly patients with stage III NSCLC with curative
intent.
In the literature, scare data are available on the outcome of
the elderly with stage III NSCLC.16–19 Although several sub-
group analyses from randomised trials suggest that elderly
patients may benefit from treatment similar to younger indi-
viduals, only a few patients were 75 years or older and they
were already selected for inclusion in studies, thus identify-
ing the fittest of all.8–13
Although the definition of the exact age limit of what ‘el-
derly’ is diverges between studies, it is clear that thephysiolog-ical status of individuals over 75 years differs from younger
patients, which may be reflected in changes in pharmacoki-
netics of drugs andorgan reserves.14,29 The observation that el-
derly patients have more haematological toxicity after the
administration of cytotoxic drugs is consistentwith these find-
ings.8,9,12–14 More important than the chronological age, the
patients’ functional age should probably determine his capac-
ity to undergo aggressive anti-cancer treatment or not.29 This
includes the evaluation of health, functional status, nutrition,
cognition and the psychosocial and economic context.
This could be achieved with the development of better
prognostic algorithms and geriatric assessments specifically
designed for elderly with lung cancer.8,9,12–14,30–36 The finding
in our series that only four patients received concurrent che-
mo-radiation reflects the uncertainty of clinicians about the
benefits versus the side-effects of this therapy in the elderly.
Although we do not have the performance status of all pa-
tients available in the registry, as performance status and co-
morbidity are strongly correlated and co-morbidity influences
significantly treatment choices, it is reasonable to assume
that more objective criteria are needed to assess the elderly
patient for which therapy he is likely to have benefit
from.19,29,37,38
It should be noted that at the time period in this series,
stage III included ‘wet’ T4 tumours with malignant pleuritis
or pericarditis. These patients were, therefore, included in
this analysis and may also explain the relatively high propor-
tion of stage III patients being treated palliatively. In other ser-
ies it was observed that elderly patients were more likely to
receive palliative treatment, although when fit, they could
be treated with curative intent with similar survival to that
of younger patients.39
As our study is based on the whole population in South
and Middle Limburg, The Netherlands, there is no selection
bias in our series. On the other hand, although the present
study is prospective, it is not randomised. However, the fact
that a median survival of 14 months and a 5-year survival
of 20% could be achieved by a treatment with curative intent
is an argument in favour of radical treatment in suitable el-
derly patients.
In summary, we have shown in a prospective population
registry that in patients over 74 years with stage III NSCLC,
treatment with curative intent was associated with long-term
outcomes that are comparable with published phase III trials
in the younger group. A defeatist approach can thus not be
supported. Nevertheless, specific trials for this age group with
appropriate assessment and prognostic tools are needed.
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